Catalent (NYSE:CTLT) Now Covered by StockNews.com

Equities researchers at StockNews.com began coverage on shares of Catalent (NYSE:CTLT) in a research note issued to investors on Monday. The firm set a “sell” rating on the stock.

Several other analysts have also issued reports on CTLT. Barclays increased their price target on shares of Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a research report on Friday, June 28th. Stephens reiterated an “equal weight” rating and issued a $63.50 price target on shares of Catalent in a research note on Thursday, April 4th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the company. According to data from MarketBeat, Catalent has an average rating of “Hold” and a consensus price target of $55.65.

Catalent Stock Performance

Shares of CTLT stock opened at $57.30 on Monday. Catalent has a 52 week low of $31.80 and a 52 week high of $60.20. The company has a market capitalization of $10.37 billion, a price-to-earnings ratio of -9.39, a PEG ratio of 2.34 and a beta of 1.16. The company has a 50-day simple moving average of $55.66 and a 200 day simple moving average of $54.64. The company has a debt-to-equity ratio of 1.37, a quick ratio of 1.77 and a current ratio of 2.51.

Catalent (NYSE:CTLT) last announced its earnings results on Wednesday, May 8th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.36). The firm had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.11 billion. Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. On average, sell-side analysts predict that Catalent will post -0.17 earnings per share for the current year.

Insider Activity

In other news, insider Ricky Hopson sold 1,401 shares of the company’s stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total value of $76,018.26. Following the completion of the transaction, the insider now owns 20,617 shares of the company’s stock, valued at $1,118,678.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.31% of the company’s stock.

Institutional Trading of Catalent

Several institutional investors have recently modified their holdings of CTLT. Thurston Springer Miller Herd & Titak Inc. bought a new position in Catalent during the 2nd quarter worth $42,000. DNB Asset Management AS increased its stake in shares of Catalent by 10.4% in the second quarter. DNB Asset Management AS now owns 30,598 shares of the company’s stock valued at $1,721,000 after buying an additional 2,887 shares during the period. GAMMA Investing LLC raised its position in shares of Catalent by 25.9% during the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after acquiring an additional 212 shares during the last quarter. DekaBank Deutsche Girozentrale raised its position in shares of Catalent by 2.4% during the first quarter. DekaBank Deutsche Girozentrale now owns 31,445 shares of the company’s stock worth $1,763,000 after acquiring an additional 732 shares during the last quarter. Finally, Redwood Grove Capital LLC lifted its stake in shares of Catalent by 23.0% in the first quarter. Redwood Grove Capital LLC now owns 308,156 shares of the company’s stock worth $17,395,000 after acquiring an additional 57,600 shares during the period.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.